NYSE:BAX

Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Retrieved on: 
Monday, April 1, 2024
Technology, Medical Devices, Hospitals, FDA, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, SYR, Novum, LVP, EMR, Patient, State, Food and Drug Administration, CQI, Hospital, Pharmacist, Baxter International, Computer security, Safety, Nursing, Baxter, Medicine, Pump, Food, Medical device

Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.
  • Offering the Novum IQ LVP in the U.S. demonstrates Baxter’s commitment to continued innovation in advancing infusion therapy.
  • “The Novum IQ platform represents a meaningful shift in how connected and intelligent infusion therapy can impact the way clinicians provide care.
  • IQ Enterprise Connectivity Suite, a scalable all-in-one server, integration engine and software application platform, designed to simplify infusion system connectivity for the Novum IQ Infusion Platform.

Baxter to Host Annual Meeting of Stockholders in Virtual Format

Retrieved on: 
Wednesday, March 27, 2024
Health Technology, Health, Medical Supplies, Online, Medtech, Central Time, Baxter International, Baxter, Annual general meeting, Holding company

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.
  • As always, whether or not a stockholder plans to attend the virtual 2024 Annual Meeting, all stockholders of record are encouraged to vote their shares prior to the 2024 Annual Meeting by one of the methods described in the proxy materials for the 2024 Annual Meeting.
  • A list of Baxter's stockholders of record will be available for examination by stockholders on the 2024 Annual Meeting website during the meeting.
  • Stockholders that have not voted their shares prior to the 2024 Annual Meeting will be able to vote their shares electronically at the 2024 Annual Meeting by clicking “Vote Here” on the meeting website.

Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

Retrieved on: 
Wednesday, February 21, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Amend, Investment, FDA, TSX, U.S. FDA, Risk, Baxter, Patient, Septic shock, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.

Key Points: 
  • TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.
  • Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”).
  • “Baxter’s continued commitment to Spectral as our exclusive supply and distribution partner being extended for a ten-year period upon U.S. FDA approval provides us with great confidence in our commercialization path,” said Chris Seto, CEO of Spectral Medical.
  • On February 15, 2024, Spectral announced that it had reached the 90-patient enrollment threshold and provided written notification to Baxter of this achievement.

Baxter to Present at Raymond James 45th Annual Institutional Investors Conference

Retrieved on: 
Thursday, February 29, 2024
Health Technology, Health, Medical Supplies, Medtech, Conference, Baxter International

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024.
  • Joel Grade, Baxter’s chief financial officer, is scheduled to present at 4:00 p.m. Eastern Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Friday, May 31, 2024.

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Retrieved on: 
Thursday, February 15, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Spectral, FDA, TSX, Baxter, Patient, Septic shock, Acceleration, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.

Key Points: 
  • TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.
  • Under the terms of the Company’s Exclusive Distribution Agreement with Baxter International (“Baxter”) (NYSE:BAX), at Interim Enrollment, Baxter has the option to make a second milestone payment to Spectral to maintain its PMX exclusive distribution rights.
  • As such, Spectral has formally notified Baxter of reaching its Interim Enrollment target of 90 patients.
  • “Enrolling patient 90 represents a major milestone in many ways for Spectral as we continue to see acceleration across our Tigris trial sites and building confidence and momentum towards completing the trial,” said Chris Seto, CEO of Spectral Medical.

Baxter Declares Quarterly Dividend

Retrieved on: 
Monday, February 12, 2024
Health, Health Technology, Baxter International

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
  • The dividend is payable on April 1, 2024, to stockholders of record as of March 1, 2024.
  • The indicated annual dividend rate is $1.16 per share of common stock.

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 8, 2024
Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Optical, Biotechnology, EPS, Task force, DNA, Nursing care plan, Piperacillin, Noise, Corporate social responsibility, FDA, Corporation, Medicine, UN, Dow Jones, EMR, Failure, Baxter International, Growth, Perioperative, TCFD, DJSI, Patient, Tazobactam, Centrella, Skin, Thrombin, Risk, Warburg Pincus, Acute liver failure, Galaxy, PD, NuVasive, Peritoneal dialysis, Risk management, Advent International, BPS, Sale, Eye, CST, Pharmaceutical industry

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
  • For full-year 2023, net income attributable to Baxter on a U.S. GAAP basis totaled $2.66 billion, or $5.25 per diluted share.
  • In 2023, the company was named to the Dow Jones Sustainability Index (DJSI) North America, which has included Baxter each year since it launched in 2005.
  • For full-year 2024: Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.

Baxter Funds University Scholarships to Support Students From Underrepresented Groups and Communities in the UK and Ireland

Retrieved on: 
Thursday, January 18, 2024
Teens, Medical Devices, Surgery, Hospitals, Health Insurance, Family, University, Consumer, Health, Education, ACT, Student, UCL, Baxter, Trinity College, Refugee, Employment, Faculty, Partnership, Science, Medtech, Trinity College Dublin, Baxter International, Dublin City University, Nursing

Baxter’s funding will support 10 students in total over the 2023/2024 and 2024/2025 academic years.

Key Points: 
  • Baxter’s funding will support 10 students in total over the 2023/2024 and 2024/2025 academic years.
  • “Through our Activating Change Today (ACT) initiative, Baxter has proudly created several programs that support students in the U.S. who are pursuing health and science degrees.
  • The scholarships will be awarded based on financial need to UK students of Black-African or Black-Caribbean descent.
  • Trinity College Dublin will offer three scholarships to undergraduate ethnic minority students through its Trinity Access Program, which aims to increase participation in higher education by students from underrepresented groups and communities in Ireland.

Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors

Retrieved on: 
Thursday, January 4, 2024
General Health, Health, Medical Supplies, Baxter International, Central Time, Webcast, Medtech

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time.
  • To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information.
  • This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com .
  • The conference call will be recorded by Baxter and is copyrighted material.

Spectral Medical Provides November Tigris Trial Update

Retrieved on: 
Monday, December 4, 2023
Sepsis, Risk, Probability, Septic shock, FDA, Mortality, Randomized controlled trial, Lipopolysaccharide, PMX, TSX, Patient, Pharmaceutical industry

Currently 20 Tigris trial sites, with near term onboarding of new, high quality clinical sites.

Key Points: 
  • Currently 20 Tigris trial sites, with near term onboarding of new, high quality clinical sites.
  • Dr. John Kellum, Chief Medical Officer of Spectral, commented, “In November we experienced strong enrollment into Tigris despite the U.S. Thanksgiving holiday, with five patient enrollments in the last six weeks.
  • Overall, we are rapidly advancing our Tigris trial and remain highly encouraged by the outlook, given the fact preliminary mortality data continues to exceed our expectations.”
    “We continue to be very bullish on the outcome of the Tigris trial.
  • Current results from Tigris are far in excess of this threshold,” said Chris Seto, Chief Executive Officer of Spectral.